Liposomes infectious diseases

A variety of other clinically important infections, such as brucellosis, listeriosis, salmonellosis, and various Mycobacterium infections, are of interest as these are often localized in organs rich in MPS cells. Liposome encapsulation has been demonstrated to improve therapeutic indices of several drugs in a number of infectious models. The natural avidity of macrophages for liposomes can also be exploited in the application of the vesicles as carriers of immunomodulators to activate these cells to an microbicidal, antiviral, or tumoricidal state. These studies were recently reviewed by Emmen and Storm (1987), Popescu et al. (1987), and Alving (1988). In addition to the treatment of "old" infectious diseases, the concept of MPS-directed drug delivery is of considerable interest for the therapy AIDS, possibly enabling control of human immunodeficiency virus replication in human macrophages. 

Allen, T. M. (1989). Stealth liposomes Avoiding reticuloendothelial uptake, in Liposomes in the Therapy of Infectious Diseases and Cancer (G. Lopez-Berestein and I. J. Fidler, eds.), Alan R. 

Pulmonary delivery of liposomes has focused on the treatment of asthma, infectious diseases, genetic diseases (cystic fibrosis), and lung injury and lately on gene therapy. 

Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 340(10) 764-71. 

Here, we present methods of preparation of liposomal vaccines and results obtained in our laboratories with small unilamellar liposomes as carriers of antigen peptides and peptide encoding DNA plasmids, demonstrating their high potential as therapeutic vaccine formulations against infectious diseases and cancers. 

Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Des 2002 8(6) 441-454. 

Coune, A. (1988) Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience. Infection 16,141-147. 

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients 2-year treatment outcomes in Bihar, India. Clinical Infectious Diseases. 2011 53(7) e91-e98. 

Virus-liposomes (virosomes) Veuous ulcers Infectious diseases Epsteiu-Barr virus Hepatitis B, Hepatitis C HfV/AIDS Tetanus Carpal tunnel syndrome Epilepsy Multiple sclerosis Parkinson s disease Ocular diseases Glaucoma Retinitis pigmentosa... 

---